ATA3219 is an Allogeneic CAR T-Cell Therapy Targeting CD19+ B Cells to Potentially Address the Root Cause of Lupus Nephritis (LN)ATA3219 Is Designed to Combine the Natural Biology of Unedited T Cells and the Benefits of an Allogeneic CAR T Approach With Preclinical Data Demonstrating Potential Efficacy in LNSecond I.
Ebvallo™ EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023Discussions with FDA Progressing on Potential U.S. BLA for Tab-cel®ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023Cash Runway Extended into Q2 2024THOUSAND OAKS, Calif. (BUSINESS WIRE) $ATRA #CART Atara Biotherapeut.